We are live on ! Find out more
UBS Group

UBS Group Portfolio holdings

AUM $666B
1-Year Est. Return 30.12%
 

UBS Group AG, formed through the 1998 merger of Union Bank of Switzerland and Swiss Bank Corporation with roots dating back to 1862, is a Swiss multinational investment bank and financial services firm headquartered in Zurich. Renowned for its dominance in wealth management, UBS serves high-net-worth individuals and families globally, managing trillions in assets, while also offering investment banking, asset management, and retail banking services in Switzerland. The firm has weathered significant challenges, including a major bailout during the 2008 financial crisis, but has since refocused on stability and sustainable growth, emphasizing digital transformation and ESG (environmental, social, governance) investing. With a strong European base and a global reach, UBS remains a cornerstone of the international financial landscape.

This Fund
S&P 500
This Quarter Est. Return
-11.87%
1 Year Est. Return
+30.12%
3 Year Est. Return
+86.21%
5 Year Est. Return
+101.56%
10 Year Est. Return
+336.66%
AUM
$221B
AUM Growth
-$31.8B
Cap. Flow
+$2.77B
Cap. Flow %
1.26%
Top 10 Hldgs %
15.08%
Holding
8,767
New
731
Increased
3,710
Reduced
3,260
Closed
648

Sector Composition

Rank Sector Weight
1 Technology 8.03%
2 Financials 6.64%
3 Healthcare 6.26%
4 Consumer Discretionary 5.11%
5 Industrials 4.91%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MENV
6976
DELISTED
AdvisorShares North Square McKee ESG Core Bond ETF
MENV
$15K ﹤0.01%
627
+276
+79% +$6.85K
WVFC
6977
DELISTED
WVS Financial Corp
WVFC
$15K ﹤0.01%
1,028
+200
+24% +$2.99K
TCCO
6978
DELISTED
Technical Communications Corporation
TCCO
$15K ﹤0.01%
+5,773
New +$21.1K
FNJN
6979
DELISTED
Finjan Holdings, Inc.
FNJN
$15K ﹤0.01%
5,967
+669
+13% +$2.24K
TRPX
6980
DELISTED
Therapix Biosciences Ltd.
TRPX
$15K ﹤0.01%
4,612
+3,030
+192% +$17.6K
BLPH
6981
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
$15K ﹤0.01%
1,267
+189
+18% +$2.74K
AREX
6982
DELISTED
Approach Resources Inc.
AREX
$15K ﹤0.01%
16,761
-2,366
-12% -$3.62K
DEST
6983
DELISTED
Destination Maternity Corporation
DEST
$15K ﹤0.01%
5,121
+4,786
+1,429% +$19.9K
BERN
6984
DELISTED
Bernstein U.S. Research Fund
BERN
$15K ﹤0.01%
600
CBK
6985
DELISTED
Christopher & Banks Corporation
CBK
$15K ﹤0.01%
32,036
+30,259
+1,703% +$15.9K
DDBI
6986
DELISTED
Legg Mason ETF Investment Trust Legg Mason Developed ex-US Diversified Core ETF
DDBI
$15K ﹤0.01%
600
MACK
6987
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$15K ﹤0.01%
5,015
+2,207
+79% +$7.65K
ESNC
6988
DELISTED
EnSync Inc
ESNC
$15K ﹤0.01%
82,466
+67,993
+470% +$14.7K
TIK
6989
DELISTED
Tel-Instrument Electronics Corp.
TIK
$15K ﹤0.01%
+4,020
New +$11.5K
MOC
6990
DELISTED
Command Security Corporation
MOC
$15K ﹤0.01%
5,370
+3,864
+257% +$10.8K
UAG
6991
DELISTED
ETRACS UBS Bloomberg CMCI Agriculture ETN
UAG
$15K ﹤0.01%
1,870
+100
+6% +$1.65K
ADIL
6992
Adial Pharmaceuticals
ADIL
$7.42M
$14K ﹤0.01%
4
+3
+300% +$4.79K
AFIF icon
6993
Anfield Universal Fixed Income ETF
AFIF
$227M
$14K ﹤0.01%
+1,420
New +$14.2K
ANY icon
6994
Sphere 3D
ANY
$18M
$14K ﹤0.01%
66
+54
+450% +$12.2K
APT icon
6995
Alpha Pro Tech
APT
$51M
$14K ﹤0.01%
3,888
+70
+2% +$249
ASRV icon
6996
AmeriServ Financial
ASRV
$77.7M
$14K ﹤0.01%
3,494
+3,203
+1,101% +$13.5K
ATXS
6997
DELISTED
Astria Therapeutics
ATXS
$14K ﹤0.01%
+515
New +$19.5K
BW icon
6998
Babcock & Wilcox
BW
$1.39B
$14K ﹤0.01%
3,442
+2,292
+199% +$20.4K
CLDX icon
6999
Celldex Therapeutics
CLDX
$2.97B
$14K ﹤0.01%
4,546
+4,340
+2,107% +$21.3K
CLGN icon
7000
CollPlant Biotechnologies
CLGN
$5.43M
$14K ﹤0.01%
3,316
-6,515
-66% -$34K

Similar funds

UBS Group's Q4 2018 Portfolio in Review

As of Q4 2018, UBS Group held 8,767 positions worth $221B, down 13% from $252B the previous quarter. Its ten largest holdings account for 15% of the portfolio.

UBS Group's Q4 2018 filing shows 731 new, 3,710 increased, 3,260 reduced and 648 closed positions. Its largest new stake was Linde: 4,971,408 shares worth $776M. The largest sale was Energy Transfer Partners, L.P., an estimated $1.06B.

By sector, the portfolio is most concentrated in Technology at 8% of assets, down from 9.3% a quarter earlier, followed by Financials and Healthcare.

  • UBS Group's largest Q4 2018 buy was Linde: 4,971,408 shares worth $776M.
  • UBS Group added most to State Street SPDR S&P 500 ETF Trust in Q4 2018, an estimated $1.82B increase.
  • UBS Group's biggest Q4 2018 reduction was Colgate-Palmolive, cutting an estimated $665M.
  • UBS Group fully exited Energy Transfer Partners, L.P. in Q4 2018, selling an estimated $1.06B.
  • UBS Group's ten largest holdings make up 15% of its $221B portfolio in Q4 2018.
  • UBS Group opened 731 new positions and closed 648 in Q4 2018.
  • UBS Group's portfolio value fell 13% quarter-over-quarter to $221B.

Based on UBS Group's 13F filing for Q4 2018, filed 14 Feb 2019.